Abstract
Lupus is a prototype autoimmune disease with unknown etiology. The disease is complex; presented with diverse clinical manifestations caused by different disease mechanisms. The complex nature of lupus immunopathology has provided a fertile field to investigate disease mechanisms and explore new approaches for therapy. However, it is also this complexity that is hampering efforts to identify therapies that benefit most patients. In this chapter, we will briefly allude to some of the known immunological defects encountered in lupus and summarise recent advance in identifying new susceptibility genetic factors. We will also provide an overview of biological agents used for treatment of patient groups and new directions for gene therapy.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mageed RA, Prud’homme GJ (2003) Immunopathology and the gene therapy of lupus. Gene Therapy 10: 861–874
Rhodes B, Vyse TJ (2008) The genetics of SLE: an update in the light of genome-wide association studies. Rheumatol 47: 1603–1611
Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM (1992) A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35: 311–318
Alarcon-Segovia D, Alarcon-Requelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR, Pons-Estel BA, Grupo Latinoamericano de Estudio del lupus Eritematoso (GLADEL) (2005) Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 52: 1138–1147
Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22: 431–456
Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, Heward JM, Gough SCL, de Smith A, Blakemore AIF et al. (2007) FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 39: 721–723
Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, de Silva U, Bailey SL, Witte T, Vyse TJ et al. (2007) Mutations in the gene encoding the 30–50 DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 39: 1065–1067
Linterman MA, Rigby RJ, Wong RK, Yu D, Brink R, Cannons JL, Schwartzberg PL, Cook MC, Walters GD, Vinuesa CG (2009) Follicular helper T cells are required for systemic autoimmunity. J Exp Med 206: 561–576
Mudd PA, Teague BN, Farris AD (2006) Regulatory T cells and systemic lupus erythematosus. Scand J Immunol 64: 211–218
Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC (2001) Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 166: 4216–4222
Horwitz DA, Tang FL, Stimmler MM, Oki A, Gray JD (1997) Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28: evidence for impaired T cellaccessory cell interaction. Arthritis Rheum 40: 822–833
Sierakowski S, Kucharz EJ, Lightfoot RW, Goodwin JS (1989) Impaired T-cell activation in patients with systemic lupus erythematosus. J Clin Immunol 9: 469–676
Wong HK, Kammer GM, Dennis G, Tsokos GC (1999) Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol 163: 1682–1689
Yi Y, McNerney M, Datta SK (2000) Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 165: 6627–6634
Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201: 703–711
Reininger L, Winkler T, Kalberer CP, Jourdan M, Melchers F, Rolink AG (1996) Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB × NZW)F1 mice. J Exp Med 184: 853–861
Wakeland EK, Liu K, Graham RR, Behrens TW (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15: 397–408
Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF (2008) B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223: 284–299
Folzenlogen D, Hofer MF, Leung DY, Freed JH, Newell MK (1997) Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol 83: 199–204
Zouali M, Sarmay G (2004) B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum 50: 2730–2741
Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MG, Kimberly RP (1996) Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 97: 1348–1354
Rönnblom L, Eloranta ML, Alm GV (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54: 408–420
Dauphinee MJ, Kipper SB, Wofsy D, Talal N (1981) Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 127: 2483–2487
Kammer GM (1999) High prevalence of T cell type I protein kinase A deficiency in systemic lupus erythematosus. Arthritis Rheum 42: 1458–1465
Tanaka T, Saiki O, Negoro S, Igarashi T, Kuritani T, Hara H, Suemura M, Kishimoto S (1989) Decreased expression of interleukin-2 binding molecules (p70/75) in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 32: 552–559
Prud’homme GJ, Kono DH, Theofilopoulos AN (1995) Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-1 and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol 32: 495–503
Rönnblom L, Pascual V (2008) The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17: 394–399
Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS (1991) Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 18: 1621–1622
Dueymes M, Barrier J, Besancenot JF, Cledes J, Conri C, Dien G, Drosos AA, Dueymes JM, Galanaud P, Grobois B et al. (1993) Relationship of interleukin-4 to isotypic distribution of antidouble-stranded DNA antibodies in systemic lupus erythematosus. Int Arch Allergy Immunol 101: 408–415
Santiago ML, Fossati L, Jacquet C, Muller W, Izui S, Reininger L (1997) Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 185: 65–70
Garaud S, Le Dantec C, Jousse-Joulin S, Hanrotel-Saliou C, Saraux A, Mageed RA, Youinou P, Renaudineau Y (2009) IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol 182: 5623–5632
Casciola-Rosen LA, Anhalt G, Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1317–1330
Hagiwara E, Gourley MF, Lee S, Klinman DK (1996) Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 39: 379–385
Alleva DG, Kaser SB, Beller DI (1998) Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. J Immunol 161: 6878–6884
Huang FP, Feng GJ, Lindop G, Stott DI, Liew FY (1996) The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRLMP-lprlpr mice. J Exp Med 183: 1447–1459
Jacob CO, McDevitt HO (1988) Tumour necrosis factor-α in murine autoimmune ‘lupus’ nephritis. Nature 331: 356–358
Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS (2007) Effects of shortterm infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 56: 274–279
Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA (1998) Decreased production of TGFbeta by lymphocytes from patients with systemic lupus erythematosus. J Immunol 160: 2539–2545
Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK et al. (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40: 204–210
Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV et al. (2008) Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358: 900–909
James JA, Harley JB, Scofield RH (2006) Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 18: 462–467
Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, Hebert M, Jones KN, Shu Y, Kitzmiller K et al. (2007) Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 80: 1037–1054
Cunninghame Graham DS, Graham RR, Manku H, Wong AK, Whittaker JC, Gaffney PM, Moser KL, Rioux JD, Altshuler D, Behrens TW et al. (2008) Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 40: 83–89
Lane P (2000) Role of OX40 signals in coordinating CD4T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med 191: 201–206
Ito T, Wang YH, Duramad O, Hanabuchi S, Perng OA, Gilliet M, Qin FX, Liu YJ (2006) OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci USA 103: 13138–13143
Stuber E, Strober W (1996) The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 183: 979–989
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100: 2610–2615
Braun D, Caramalho I, Demengeot J (2002) IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 14: 411–419
Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM (2003) Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 63: 6424–6431
Cornall R, Cyster J, Hibbs M, Dunn A, Otipoby K, Clark A, Goodnow CC (1998) Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8: 497–508
Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA (2005) Decreased Lyn expression and translocation to lipid raft signalling domains in B-lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 52: 3955–3965
Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415–1421
Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O’Shea JJ, Biron CA (2002) Critical role for STAT4 activation by type 1 interferons in the interferongamma response to viral infection. Science 297: 2063–2066
Moynihan TP, Cole CG, Dunham I, O’Neil L, Markham AF, Robinson PA (1998) Finemapping, genomic organization, and transcript analysis of the human ubiquitinconjugating enzyme gene UBE2L3. Genomics 51: 124–127
Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA (2003) Increased ubiquitination and reduced expression of Lck in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 48: 1343–1354
Yousefi S, Simon HU (2007) Apoptosis regulation by autophagy gene 5. Crit Rev Oncol Hematol 63: 241–244
Youinou P, Taher TE, Mankaï A, Berthou C, Mageed RA (2008) Anti-CD20 in targeting B-lymphocytes for the treatment of autoimmune diseases. Clinical benefits and insights into the role of B-lymphocytes in pathophysiology. Immunol Endocrine Metabol Agents Med Chem 8: 222–234
Lu T, Ng KP, Cambridge G, Leandro MJ, Edwards JCW, Ehrenstein M, Isenberg DA (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61: 482–487
Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR (2006) Initial clinical trial of Epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8: R74
Coutts SM, Plunkett ML, Iverson GM, Barstad PA, Berner CM (1996) Pharmacological intervention in antibody mediated disease. Lupus 5: 158–159
Alarcón-Segovia D, Tumlin J, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B; LJP 394 Investigator Consortium (2003) LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebocontrolled study. Arthritis Rheum 48: 442–454
Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293: 2111–2114
Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44: 1313–1319
Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A, Diamond B, Madaio MP, Davidson A (2004) Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 173: 3524–3534
Furie R, Stohl W, Ginzler E, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J et al. (2008) Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 10: R109
Ding C (2008) Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther 8: 1805–1814
Dall’Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C et al. (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56: 4142–4150
Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97: 2063–2073
García-Cózar FJ, Molina IJ, Cuadrado MJ, Marubayashi M, Peña J, Santamaría M (1996) Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 104: 72–79
Kalunian KC, Davis Jr, JC, Merrill JT, Totoritis MC, Wofsy D, for the IDEC-131 Lupus Study Group (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154. Arthritis Rheum 46: 3251–3258
Kawai T, Andrews D, Colvin R, Sachs D, Cosimi A (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6: 114
Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265: 1225–1227
Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114–1123
Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY (2006) Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunol 119: 296–305
Choy E (2009) RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists. Nat Clin Pract Rheumatol 5: 66–67
Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M (1994) Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179: 305–310
Llorente L, Richaud-Patin Y, García-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcón-Segovia D, Wijdenes J et al. (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43: 1790–1800
Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of TNFα blockage in systemic lupus erythematosus — an open label study. Arthritis Rheum 50: 3161–3169
Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43: 2383–2390
Pascual V, Farkas L, Banchereau J (2006) Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 18: 676–682
Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, Emilie D, Peltre G, Bensussan A, Bizzini B et al. (2009) IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 106: 5294–5299
Wang Y, Hu Q, Madri J, Rollins S, Chodera A, Matis L (1996) Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 93: 8563–8568
Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ (2005) C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 35: 2496–2506
Robak E, Robak T (2009) Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets 10: 26–37
Macanovic M, Lachmann PJ (1997) Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 108: 220–226
Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Möröy T (2000) Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25: 177–181
Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, Kuroda Y (2001) Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 28: 313–314
Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R et al. (2009) Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Int Immunol 21: 237–243
Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, Tsokos GC (2003) Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum 48: 1948–1955
Raz E, Dudler J, Lotz M, Baird SM, Berry CC, Eisenberg RA, Carson DA (1995) Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 4: 286–292
Fujio K, Okamura T, Okamoto A, Yamamotot K (2007) cell receptor gene therapy for autoimmune diseases. Ann N Y Acad Sci 1110: 222–232
Ding H, Wu X, Wu J, Yagita H, He Y, Zhang J, Ren J, Gao W (2006) Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol 118: 258–267
Ye X, Zhu T, Bastacky S, McHale T, Li J, Xiao X (2005) Prevention and reversal of lupus in NZB/NZW mice by costimulatory blockade with adeno-associated virus-mediated gene transfer. Arthritis Rheum 52: 3975–3986
Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190: 1697–1710
Liu W, Szalai A, Zhao L, Liu D, Martin F, Kimberly RP, Zhou T, Carter RH (1995) Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 50: 1884–1896
Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603–607
Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders H-J (2007) Inhibition of toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 18: 1721–1731
Muraoka M, Hasegawa H, Kohno M, Inoue A, Miyazaki T, Terada M, Nose M, Yasukawa M (2006) IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr Mice. Arthritis Rheum 54: 3591–3600
Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T et al. (2004) Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatol 43: 1121–1128
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Basel
About this chapter
Cite this chapter
Mageed, R.A., Taher, T.E., Jawad, A.S. (2010). Disease mechanisms, genetic susceptibility and therapeutic approaches in lupus disease. In: Chernajovsky, Y., Robbins, P.D. (eds) Gene Therapy for Autoimmune and Inflammatory Diseases. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0346-0165-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-0346-0165-8_9
Publisher Name: Springer, Basel
Print ISBN: 978-3-0346-0164-1
Online ISBN: 978-3-0346-0165-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)